Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

547.36 -0.38 (-0.07%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
51 52 Next >
The 3 Best Biotech Stocks to Buy In July
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
Check Out What Whales Are Doing With REGN
Via Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Why Regeneron Pharmaceuticals Stock Dipped This Week
A key regulatory setback is weighing on the biotech's stock. 
Via The Motley Fool
Check Out What Whales Are Doing With REGN
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
What Will Amgen Buy Next?
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why Catalent Stock Flopped Today
The company takes the fall for a failed drug application. 
Via The Motley Fool
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
18 Analysts Have This to Say About Regeneron Pharmaceuticals
Via Benzinga
Why Regeneron Stock Is Trading Lower Today
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday
Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. (NASDAQ: WBA) from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2%... 
Via Benzinga
Why Regeneron Stock Is Falling Today
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell after the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of... 
Via Benzinga
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday. 
Via Investor's Business Daily
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
Biotech And Healthcare Stocks Lagging
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade. 
Via The Motley Fool
How to Retire Rich: Biotech Stocks Edition
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035
JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and  
Via Benzinga
2 Stocks to Buy No Matter What Happens in June and Beyond
A lot could go wrong in the next few months, but investors should largely ignore all that noise. 
Via The Motley Fool
3 Biotech Stocks to Sell in June Before They Crash and Burn
Investors should get out of these biotech stocks to sell now that the Covid-19 pandemic is largely over. These's worse in store for them. 
Via InvestorPlace
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS